Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

Arthritis and Rheumatism

Volumn 64, Issue 8, 2012, Pages 2504-2517

  Kavanaugh, Arthur ^a   Van Der Heijde, Désirée ^b   McInnes, Iain B ^c   Mease, Philip ^d   Krueger, Gerald G ^e   Gladman, Dafna D ^f   Gõmez Reino, Juan ^g   Papp, Kim ^h   Baratelle, Anna ^i,j   Xu, Weichun ^i,j   Mudivarthy, Surekha ^i,j   MacK, Michael ^i,j,k   Rahman, Mahboob U ^i,j,k   Xu, Zhenhua ^i,j,l   Zrubek, Julie ^i,j,l   Beutler, Anna ^i,j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g Instituto de Salud Carlos III   (Spain)

^h PROBITY MEDICAL RESEARCH   (Canada)

ⁱ JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^j Baratelle Associates   (United States)

^k PFIZER INC   (United States)

^l GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; DRUG ANTIBODY; GOLIMUMAB; METHOTREXATE; PLACEBO;

ABSCESS; ACUTE CHOLECYSTITIS; ADULT; ANAPHYLAXIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASAL CELL CARCINOMA; DACTYLITIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTHESITIS; FEMALE; HUMAN; INJECTION SITE ERYTHEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SEPSIS; SERUM SICKNESS; SIDE EFFECT; SUPERFICIAL THROMBOPHLEBITIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG TOXICITY; FEMALE; FOOT JOINTS; HAND JOINTS; HUMANS; INJECTIONS, SUBCUTANEOUS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84864438913     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34436     Document Type: Article

References (23)

1. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study [published erratum appears in Arthritis Rheum 2010;62:3518]. Arthritis Rheum 2008; 58: 964-75.
2. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis [published erratum appears in Arthritis Rheum 2010;62:3005]. Arthritis Rheum 2009; 60: 2272-83.
3. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study [published erratum appears in Ann Rheum Dis 2011;70:238]. Ann Rheum Dis 2009; 68: 789-96.
4. Inman RD, Davis JC Jr, van der Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58: 3402-12.
5. Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al, for the GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial [published erratum appears in Lancet 2009;374:1422]. Lancet 2009; 374: 210-21.
6. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study [published erratum appears in Arthritis Rheum 2010;62:2555]. Arthritis Rheum 2009; 60: 976-86.
7. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
8. Van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van 't Hof MA, van Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35: 26-34.
9. Van der Heijde D, Sharp J, Wassenberg S, Gladman DD,. Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis 2005; 64 Suppl II: ii61-4.
10. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
11. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68: 954-60.
12. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
13. Fries JF, Spitz P, Kraines RG, Holman HR,. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
14. Ware JE Jr, Sherbourne CD,. The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
15. Mease PJ, Ganguly R, Wanke L, Yu E, Singh A,. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Ann Rheum Dis 2004; 63 Suppl I: i391.
16. Rich P, Scher RK,. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: 206-12.
17. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewe R, van der Tempel H, Mielants H, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62: 127-32.
18. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): the extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions, E1. Fed Regist 1995; 60: 11270.
19. Van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C, et al, for the IMPACT 2 Study Group. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the Induction and Maintenance Psoriatic Arthritis Clinical Trial 2. Arthritis Rheum 2007; 56: 2698-707.
20. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-72.
21. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al, for the Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279-89.
22. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Arthritis Rheum 2007; 56: 476-88.
23. Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, et al, for the IMPACT 2 Study Group. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007; 66: 498-505.